Katie Bass, APRN
Family · Henderson, NVNPI 1619582459
Payments from drug & device makers
Across 45 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$180
- Amgen$93
- Mayne Pharma Commercial LLC$68
- Novo Nordisk$63
- Bristol Myers Squibb$50
- Astellas Pharma US Inc$50
- plus $328 from 16 others
What the payments were for
- Food & beverage$831100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $180 |
| Amgen | 4 | $93 |
| Mayne Pharma Commercial LLC | 3 | $68 |
| Novo Nordisk | 3 | $63 |
| Bristol Myers Squibb | 3 | $50 |
| Astellas Pharma US Inc | 2 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $47 |
| Pfizer | 2 | $37 |
| Dexcom, Inc. | 2 | $26 |
| Bayer | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Merck | 1 | $21 |
| Intra-sana Laboratories | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Genentech USA, Inc. | 2 | $10 |
How this compares
$831 in reported general payments places this provider in the 65th percentile of 1,501 family providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 11 | $210 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $197 |
| Dicyclomine Hcl | 16 | $167 |
| Losartan Potassium | 11 | $153 |
| Levothyroxine Sodium | 17 | $139 |
| Amlodipine Besylate | 14 | $138 |
| Metformin Hcl | 13 | $89 |
| Alprazolam | 11 | $59 |
| Lisinopril | 24 | $36 |
| Alendronate Sodium | 15 | $30 |
Paid to pharmacies, not to this prescriber.
Other family in Henderson
- Kristy SolisHenderson$23K
- Joseph LauHenderson$18K
- Judith YuHenderson$14K
- Daniel Sam AciertoHenderson$11K
- Reiko TapiaHenderson$10K
- Francis TorresHenderson$8K
- John PhoenixLas Vegas$281K
- Hollie TylerLas Vegas$118K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.